Postpartum Depression (PPD) is the most common non-psychotic complication of childbearing affecting women and represents a significant public health problem affecting women and their families.
The postnatal period is well established as an increased time of risk for the development of severe mood disorders. There are three common forms of postpartum affective illness: the blues (baby blues, maternity blues), postpartum (or postnatal) depression, and puerperal (postpartum or postnatal) psychosis, each of which differs in its prevalence, clinical presentation, and management.
Postpartum depression usually begins within 1–12 months after delivery. In some women, postpartum blues simply continue and become more severe. In others, a period of well-being after delivery is followed by a gradual onset of depression. The patterns of symptoms in women with postpartum depression are similar to those in women who have depression unrelated to childbirth.
Postpartum Depression Epidemiological Segmentation
The Epidemiological Segmentation of Postpartum Depression in 7MM from 2017 to 2030 is segmented as:-
- Total Diagnosed Prevalent Population of Postpartum Depression
- Type-specific Diagnosed Prevalence of Postpartum Depression
Postpartum Depression Epidemiology
- The total diagnosed prevalent population of Postpartum Depression in the 7MM in 2017 was 1,134,800
- The diagnosed prevalent cases of Postpartum Depression in the United States were 609,900 in 2017.
The market size of Postpartum Depression in the 7MM in 2017 was USD 138.75 Million
Postpartum Depression Market Drivers
- Increasing Cases of Postpartum Depression
- Increasing Awareness of Postpartum Depression
- Zulresso’s Positive Breastfeeding Data
- An improvement over Conventional Therapies
Postpartum Depression Market Barriers
- Adverse Side Effects Associated With Current Therapy
- Under diagnoses and Undertreatment
- Lack of Proper Diagnostic Tools
- Lack of Patient Compliance
Postpartum Depression Emerging Drugs
The emerging drugs of the Postpartum Depression market are
- Zuranolone (SAGE-217)
- Ganaxolone (CCD-1042)
And many others.
Postpartum Depression Key Players
The key players in the Postpartum Depression market are
- Sage Therapeutics
- Marinus Pharmaceuticals
And many others.